COGSTATE LTD — Board/Management Information 2011

Jun 29, 2011

==> picture [235 x 48] intentionally omitted <==

ASX ANNOUNCEMENT

Melbourne, 30 June 2011

RESIGNATION OF DIRECTORS

CogState Limited (ASX:CGS) wishes to advise that Dr Michael Wooldridge and Mr Richard Morgan have resigned as non-executive directors of the Company effective 30 June 2011.

In 2009, Dr Wooldridge led the successful bid for the new CRC for Mental Health and is its Chairman. On July 1, CogState is signing a Participant’s Agreement to join the CRC, which aims to identify biomarkers and develop diagnostic kits for the early treatment of Alzheimer’s disease, Parkinson’s disease, schizophrenia and other related disorders. As CRC guidelines prohibit any conflict of interest between participants and the CRC management or board, it is necessary for Dr Wooldridge to stand down from the board of CogState.

Mr Morgan, who is based in the United Kingdom, has been unable, in recent months, to travel to Australia on a regular basis due to personal reasons.

CogState would like to thank Dr Wooldridge and Mr Morgan for their contributions to CogState as directors and wish them all the best in the future.

Following this announcement, the CogState Board of Directors will be made up of Martyn Myer (Non-Executive Chairman), Brad O’Connor (CEO), David Simpson (Non-Executive Director) and Richard van den Broek (Non-Executive Director).

CogState does not plan to appoint replacements for Dr Wooldridge and Mr Morgan, at this time.

About CogState

CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). To date, CogState has commercialised its technology in two markets – clinical drug trials and concussion management in sport.

In the clinical drug trial market, CogState technology and associated services are used by pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials. Since sales into the clinical trials market began in 2004, CogState has secured agreements with top pharmaceutical companies including Pfizer, AstraZeneca, GlaxoSmithKline, Merck, Johnson & Johnson, Novartis, Lundbeck, Dainippon Sumitomo, Otsuka, and Servier.

In the area of sports related concussion, CogState’s technology has been used by a number of highly regarded institutions and sporting organisations around the world for almost 10 years. Current users include, University of Notre Dame, University of Michigan, English Rugby League, English Jockey Club, and a number of national and international Rugby League and Rugby Union clubs. In Australia, both the AFL and NRL have mandated computerised cognitive testing, using CogState.

==> picture [235 x 48] intentionally omitted <==

CogState has established a joint venture in the USA, called Axon Sports, to market its concussion management technology. Axon Sports has an exclusive license to market and sell the CogState technology in the area of sports and related concussions within North America (USA, Canada, Mexico).

For further information:

Brad O’Connor, Chief Executive Officer, CogState Ltd. Ph: 03 9664 1300 Mob: 0411 888 347 boconnor@cogstate.com